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Aims: For the standardization of ﬂow-mediated vasodilatation (FMD) assessment as a clinical tool,
validation of its reliability across multiple institutions and the establishment of normal/reference values
based on reliable data from multiple institutions are needed.
Methods and results: In Study 1, assessment of FMD (scan recording and analysis) using an ultrasono-
graphic semi-automatic measuring system (sFMD) was conducted at 18 participating institutions (sFMD-
INST) (n ¼ 981). All of the brachial arterial scans were also analyzed at a core laboratory (sFMD-COLB).
After 111 subjects with inadequate sFMD recordings were excluded (n ¼ 880), the correlation between
the sFMD-INST and sFMD-COLB improved from R ¼ 0.725 to R ¼ 0.838 (p < 0.001). In Study 2, based on
good-quality sFMD data obtained from 6660 subjects without cardiovascular disease (CVD) and 729
subjects with CVD from 27 institutions, reference values of sFMD are proposed by the Framingham risk
score (FRS)-based risk categories and according to gender and age. The receiver-operating characteristic
curve analysis revealed a signiﬁcant power of sFMD values in reference ranges to discriminate between
subjects with and without CVD (e.g., area under curve ¼ 0.64 in the FRS-low risk group).Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, 160-0023 Tokyo, Japan.
miyama).
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H. Tomiyama et al. / Atherosclerosis 242 (2015) 433e442434Conclusions: When the analysis was limited to cases with clear sFMD recordings, the reliability of the
sFMD assessment (scan and its analysis) conducted in individual institutions appeared to be acceptable.
Reference sFMD values (lower cuff occlusion) for the Japanese population are proposed based on reliable
data derived frommultiple institutions, and the reference values may identify patients without advanced
vascular damage.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Although assessment of ﬂow-mediated vasodilatation of the
brachial artery (FMD) has potential as a useful clinical tool in the
clinical management of patients with cardiovascular (CV) disease
and/or its risk factors [1e5], highly skilled sonographers are
required for the accurate assessment of FMD (brachial artery scan
recording and analysis) [6e8]. Therefore, in most multi-center
studies conducted to date, the brachial artery scans obtained in
each participating institution have been analyzed at a core labo-
ratory (COLB) [4,5,7,8]. For the standardization of FMD assessment
as a clinical tool, validation of the FMD assessment method across
multiple institutions and the establishment of normal/reference
FMD values based on reliable data obtained from multiple in-
stitutions fulﬁlling the criteria for reliability of the assessment
method are needed.
Recently, an ultrasound instrument dedicated to FMD assess-
ment, equipped with both an on-line computer-assisted semi-
automatic analysis software to measure the FMD and accessories
for ﬁxing the measured arm and ultrasound probe, has been
introduced for commercial use [9e12]. A major advantage of this
device is that it allows automatic direct A-mode signal analysis of
changes of the vessel diameter during the FMD assessment pro-
cedure in real time under stereotaxic guidance based on 2-
dimensional B-mode images for maintenance of the appropriate
position for the vessel interfaces recording [9e12]. Thus, this device
might be helpful for the standardization of FMD assessment via
facilitating the assessment at individual institutions and improving
the quality of analysis of the FMD scan records at each institution.
The FMD-J studywas a prospectivemulticenter study conducted
to examine the usefulness of FMD assessment using a semi-
automatic device at individual institutions in the management of
patients at risk for CV disease [9]. The present study was conducted
as an extension of the FMD-J study to examine the following for the
standardization of FMD assessment; Study 1) To validate the reli-
ability of FMD assessment (scan and its analysis) using the afore-
mentioned semi-automatic device at individual participant
institutions as compared to analysis of the brachial artery scans at a
COLB; Study 2) if the reliability was found to be acceptable, the FMD
data obtained in the FMD-J study and in the previously reported
Flow-mediated Dilatation Japan Registry study (FDR study) [11,12],
in which the FMD assessment was conducted using the same
protocol as that in the FMD-J study, would be collected to obtain the
reference values of FMD. In addition, a receiver-operating-
characteristic curve (ROC) analysis was carried out to evaluate the
discriminative power of FMD in the reference ranges for the pres-
ence of CV disease (i.e., to discriminate between subjects with and
without CV disease).2. Methods
The study protocols conform to the principles of the Declaration
of Helsinki, and have been approved by the Ethics Committee of
Tokyo Medical University (The core center of FMD-J study) (No.2456) and also by the Ethics Committees of other each of the
participating institutions. The written informed consent was ob-
tained from all of the study participants before participation in the
FMD-J study or the FDR study.
2.1. Study cohorts
The present studies were conducted in subjects derived from
study cohorts of the FMD-J study (2 study cohorts for Study 1 and 4
study cohorts for Study 2) (Fig.1). The FMD-J study included 3 study
arms (Study A, Study B, and Study C) (Fig. 1).
The details of the study protocols and the subjects are described
in Supplement ﬁle 1 and Reference 9. In the FDR study, all of the
participants underwent annual health check-ups and assessment of
FMD at one of 4 institutions (clinics/hospitals) afﬁliated to the
following 3 institutions participating in the FMD-J study {Tokyo
Medical University (COLB for the FMD-J study), National Defense
Medical College, and Hiroshima University}. Some parts of the data
from the FDR study have already been reported elsewhere [11,12].
The protocol for the assessment of FMD was the same in the FDR
study as that in the FMD-J study, and the aforementioned semi-
automatic device was used for the FMD assessment in all the sub-
jects of the FDR study. In Study C (an arm of FMD-J study) and the
FDR study, the FMD was measured at the time of the annual health
check-up in the subjects, and the presence/absence of CV disease in
the subjects (heart disease and/or cerebrovascular disease: the
details were not described) was conﬁrmed by a questionnaire.
2.2. Study design
2.2.1. Study 1: examination of the reliability of assessment of FMD
at individual participant institutions
Some of the study subjects in Study A and Study B (arms of FMD-
J study) (from 18 participating institutions) participated in Study 1
(Fig. 1). The results of assessment of the quality of the brachial ar-
tery scans and of the data analyses conducted at each institution
were registered on the WEB. Each participant institution (18 in-
stitutions) was instructed to send the USB devices containing the
brachial artery scans obtained during the assessment of FMD
without the results of the data analysis to the COLB located in Tokyo
Medical University, and the recordings were individually analyzed
by a well-experienced reader at the COLB (FMD-COLB) without any
information concerning the FMD data assessment at the participant
institution. This well-experienced reader (T.S.) had the experience
of conducting this analysis in more than 500 cases (as at the end of
December 2010). Then, the results of the FMD assessment at each of
the institutions registered on the WEB, and the FMD-COLB were
compared (Study 1-1, Study 1-2, and 1-3).
2.2.2. Study 2: establishment of reference values of FMD and
evaluation of the discriminative power of FMD for the presence of
CV disease
In addition to the subjects from Study B, subjects without CV
disease from Study C and the FDR study [11,12] were enrolled for
Fig. 1. Flow-chart of the study subject selections. Abbreviations FMD ¼ ﬂow-mediated vasodilatation of brachial artery; FRS ¼ Framingham risk score; eGFR ¼ estimated glomerular
ﬁltration rate; CV risk ¼ risk factors for cardiovascular disease; CV disease ¼ cardiovascular disease; IMC ¼ intimaemedia complex.
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values were obtained. A ROC analysis was carried out to evaluate
the discriminative power of FMD for subjects with and without CV
disease (Study 2-2).
2.2.2.1. Study 2-1-1: FMD values in the Framingham Risk Score (FRS)-
based CV risk classes (Fig. 1). The values of FMD were examined in
subjects without CV disease classiﬁed into different CV risk cate-
gories based on the FRS. Then, they were divided by the gender and
the FRS-based CV risk category (high-risk; 10-year CAD risk 20%/
intermediate-risk; 10-year CAD risk 10e19%/low-risk; 10-year CAD
risk <10%) [13].
2.2.2.2. Study 2-1-2: age-based reference values (Fig. 1). The refer-
ence values were examined in subjects who did not have a history
of CV disease, values of the serum creatinine-derived estimated
glomerular ﬁltration rate (eGFR) of <60 ml/min/1.73 m2 [14], and
were not receiving medications for CV risk factors. Then, the sub-
jects were divided by the gender and age (divided in decades).
2.2.2.3. Study 2-1-3: age-based normal values (Fig. 1). The normal
values were examined in subjects for establishing age-based
reference values, after excluding subjects with risk factors for CV
disease (current smoker, BMI  27.5, SBP/DBP  140/90 mm Hg,
TC  6.2 mmol/L, HbA1c  6.5%, and/or medication for hyperten-
sion, dyslipidemia, and/or diabetes mellitus). In addition, women
who were menstruating at the time of the FMD assessment were
also excluded. Then, the subjects were divided by the gender and
age (classiﬁed in decades).
2.2.2.4. Study 2-2: FMD values in subjects with CV disease (Fig. 1).
In addition to subjects from Study A, subjects with CV disease from
Study C and the FDR study were also enrolled, and the FRSs were
calculated in these subjects.2.3. FMD procedures, brachial artery scan, assessment of the quality
of the scans, and their analysis
In the FMD-J study, two ultrasound instruments equipped with
an on-line computer-assisted semi-automatic analysis software
were available tomeasure the FMD: EF (Unex Co. Ltd, Nagoya, Japan
and e-TRACKING (ALOKA Co. Ltd, Tokyo, Japan) [9]. Except for the
case of 10 subjects in Study A, however, the Unex equipment was
used for the assessment of FMD in all the study subjects, because it
is an even more dedicated equipment to assess FMD than e-
TRACKING.
In regard to the procedure for the FMD assessment, an occlusion
cuff is wrapped around the forearm with the proximal edge of the
cuff at the elbow, and cuff is inﬂated to a compression pressure of
50 mm Hg over the systolic blood pressure value for 5 min. The
details of these procedures and the device used to measure the
values of FMD are described in supplemental ﬁle 2. In this system,
the diastolic diameter of the brachial artery is determined semi-
automatically and the changes of the diameter are tracked auto-
matically [9].
Inadequate scans were assessed to check which of the following
two criteria for inadequate scans were met; exclusion criterion
1 ¼ vessel interfaces in the longitudinal B-mode images not clear
and/or the images inadequate due to patient movement; exclusion
criterion 2 ¼ exclusion criteria 1 plus unclear signal of the IMC in
the A-mode images. In cases where the IMC was clear in the A-
mode images, the diameter was automatically determined from the
peak of the IMC signal (Fig. 2A), and such cases were considered as
not falling under exclusion criteria 2. In cases without a clear signal
of the IMC, the diameter was manually determined by the rising
point of the media-adventitia signals (Fig. 2B), and such cases were
considered as not falling under exclusion criteria 1. FMD was
calculated as {Diameter of the brachial artery at the baseline
(DIAbase) - diameter of the brachial artery at maximum dilatation
(DIAmax)} x 100/DIAbase. In addition, because DIAbase is an
Fig. 2. Images of ﬂow-mediated vasodilatation with/without clear intimaemedia complex signals.
H. Tomiyama et al. / Atherosclerosis 242 (2015) 433e442436
Table 1
Clinical characteristics of the subjects in each study.
Study subjects Study 1 Study 2-1s Study 2-2
Number of subjects 981 6660 729
Gender (men/women) 660/321 5269/1391 620/109
Age (y) 63 ± 9 50 ± 10 63 ± 9
SBP (mm Hg) 131 ± 18 127 ± 16 128 ± 17
DBP (mm Hg) 77 ± 10 80 ± 12 77 ± 10
HR (beats/min) 64 ± 10 64 ± 10 63 ± 10
Current smoker (%) 124 (12.6)#1 2982 (31.3)#2 119 (16.3)#3
BMI 25.0 ± 3.6 23.4 ± 3.3 24.8 ± 3.6
TC (mmol/L) 4.7 ± 0.9 5.3 ± 0.8 4.5 ± 0.9
HDL (mmol/L) 1.4 ± 0.4 1.5 ± 0.4 1.3 ± 0.4
TG (mmol/L) 1.5 ± 1.0 1.4 ± 1.1 1.6 ± 1.1
FBG (mmol/L) 6.2 ± 1.7 5.5 ± 1.0 6.4 ± 1.9
Crnn (mmol/L) 72 ± 21 72 ± 16 77 ± 33
eGFR (mL/min/1.73m2) 72 ± 17 78 ± 14 71 ± 17
FMD-INST (%) 4.87 ± 2.63 6.38 ± 3.07 4.82± 2.70
FMD-INSTallo (%) 5.68 ± 3.08 7.40 ± 3.51 5.63 ± 3.13
FMD-COLB (%) 4.63 ± 2.78 e e
DIAbase-INST (mm) 4.20 ± 0.66 4.03 ± 0.58 4.26 ± 0.62
DIAbase-COLB (mm) 4.19 ± 0.65 e e
DIAmax-INST (mm) 4.40 ± 0.65 4.28 ± 0.57 4.46 ± 0.61
DIAmax-COLB (mm) 4.38 ± 0.64 e e
Medications [n (%)]
For hypertension 917 (93.5) 1492 (22.4) 601 (82.4)
For dyslipidemia 618 (63.0) 604 (9.1) 570 (78.2)
For diabetes mellitus 212 (21.6) 299 (4.5) 211 (28.9)
CVD (%) 469 (47.8) 0 729 (100)
FRS 3.9 ± 4.6 6.5 ± 3.2
FRSclass (L/M/H) (%) 4424/1630/481
(67.7/24.9/7.4)
290/255/119
(43.7/38.4/17.9)
Not Calc FRS 125 65
Abbreviations: Study 1 ¼ study subjects for examination of the reliability of FMD
assessment in each participant institute; Study 2-1s ¼ study subjects without car-
diovascular disease for examination of FMD in subjects without cardiovascular
disease of different FRS classes and of age-based normal/reference values of FMD;
Study 2-2 ¼ study subjects with a history of cardiovascular disease for examination
of FMD; SBP ¼ systolic blood pressure; DBP ¼ diastolic blood pressure; HR ¼ heart
rate; Current Smoker ¼ number of current smokers; BMI ¼ body mass index;
TC¼ serum level of total cholesterol; TG¼ serum level of triglycerides; HDL¼ serum
level of high-density lipoprotein cholesterol; FBG ¼ fasting blood glucose level;
Crnn ¼ serum level of creatinine; eGFR ¼ estimated glomerular ﬁltration rate;
FMD ¼ ﬂow-mediated dilatation of the brachial artery; FMD-INSTallo ¼ allometric
scaled FMD-INST; DIAbase ¼ baseline diameter of the brachial artery;
DIAmax¼ diameter of the brachial artery at maximum dilatation; -COLB¼ analyzed
by the core laboratory: -INST¼ analyzed at each participant institution; Medication:
number of subjects receiving medications; CVD ¼ number of subjects with cardio-
vascular disease; FRS ¼ Framingham risk score; FRS class ¼ risk classiﬁcation based
on the Framingham risk score; L ¼ low risk; M ¼ intermediate risk; H ¼ high risk;
Not Calc FRS¼ number of subjects in whom the Framingham risk score could not be
calculated because of data loss/age over 75 years; #1 ¼ smoking history was not
available for 18 subjects; #2 ¼ smoking history was not available for 22 subjects;
#3 ¼ smoking history was not available for 23 subjects.
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of FMD for future cardiovascular events, the allometric scaled FMD
(DIAmax/DIAbase 0.89) was also calculated [15].
2.4. Training and certiﬁcation for the assessment of FMD
See Supplementary ﬁle 3.
2.5. Statistics
The data were expressed as mean ± SD or median with 95%
conﬁdence intervals (CI). The relationships among the variables
were assessed by univariate linear regression analysis and
stepwise multiple linear regression analysis. BlandeAltman plots
were used to assess the variability of the FMD measurements
between the institutions and the COLB. For assessing the inter-
rater reliability, the intra-class correlation coefﬁcient (ICC) was
calculated. In all the analyses, a p value of less than 0.05 was
considered to indicate a statistically signiﬁcant difference. ROC
analysis was conducted to determine the discriminative power
of FMD for the risk of CV disease in the subjects, and the area
under the curve (AUC) was calculated. All the analyses were
conducted using the IBM/SPSS (22.0J for Windows, IBM/SPSS
Inc., Chicago, IL).
3. Results
3.1. Study 1: validation of the reliability of FMD assessment across
the participating institutions
A total of 981 brachial artery scans obtained for FMD assessment
were sent to the COLB from the 18 participating institutions (Study
1-1: Fig. 1).
The reliability of the assessment of FMD from these 981 records
at the individual institutions was assessed. The clinical charac-
teristics of the study subjects are shown in Table 1. Based on the
reports registered on the WEB, the scans were deemed as
adequate in 880 of the 981 subjects (Study 1-2: Fig. 1), the
remaining falling under exclusion criterion 1 {unclear images of
the brachial artery interfaces (n ¼ 79) or patient movement
(n ¼ 22)}, and the correlation coefﬁcient of the FMD values
improved after exclusion of the inadequate scans (from R ¼ 0.725
to R ¼ 0.838) (Fig. 3).
Of these 880 scans, clear IMC signals were obtained in 814
(Study 1-3: Fig. 1), the remaining falling under exclusion criterion
2, but no further improvement of the correlation coefﬁcient was
observed after exclusion of the latter scans (Fig. 3). The National
Defense Medical college and Hiroshima University participated in
the FDR study, and in the present study, the correlation co-
efﬁcients between the FMD-COLB and FMD values analyzed at
these two institutions and their ICC values were found to be
acceptable {R ¼ 0.868, P < 0.001, ICC ¼ 0.862 (0.811e0.900) and
R ¼ 0.862, P < 0.001, ICC ¼ 0.964 (0.787e0.914)}. BlandeAltman
analysis showed no systemic bias in the FMD measurement vari-
ability between the institutions and the COLB (Fig. 3). The stan-
dard deviation of the difference of the FMD values between each
of the institutions and the COLB was 0.25 ± 1.55%. The ICC values
of two institutions were not satisfactory (i.e., ICC <0.60)
(Supplementary Table 1). As compared to the other institutions for
which the ICC values were determined to be 0.60 (i.e., good
inter-rater reliability), the number of study subjects enrolled from
these two institutions was small (n ¼ 9 each), and both in-
stitutions participated in only Study A. Correlations between the
diameters of the brachial artery analyzed at each participant
institution and the core laboratory and the BlandeAltman plotsare depicted in supplementary Figs. 1 and 2.3.2. Study 2: establishment of reference FMD values and evaluation
of the discriminative power of FMD for the presence of CV disease
The ﬂow-chart for the study subject selections is shown in Fig. 1.
Among the data of a total of 7627 subjects without CV disease from
study B, study C and the FDR study (data from two institutions with
ICC values of <0.60 were not included), clear images of the brachial
artery interfaces were obtained in 6660 subjects (87.3%) (Fig.1). The
clinical characteristics of the study subjects are shown in Table 1.
The FRSs were calculated in 6535 of the 6660 subjects (after
exclusion of subjects aged over 75 years). In these 6535 subjects, a
stepwise multivariate linear regression analysis demonstrated that
the age (beta ¼ 0.105, p < 0.001), gender (men ¼ 1 and
women ¼ 0) (beta ¼ 0.204, p < 0.001), and FRS (beta ¼ 0.085,
p < 0.001) were signiﬁcantly associated with the FMD, independent
Fig. 3. Correlations between ﬂow-mediated dilatation of the brachial artery analyzed at each participant institution and the core laboratory and BlandeAltman plots for variability
of the ﬂow-mediated dilatation measurement between each participant institution and the core laboratory. Abbreviations FMD ¼ ﬂow-mediated vasodilatation of the brachial
artery; -COLB ¼ analyzed at the core laboratory: -INST ¼ analyzed at each participant institution; -Diff ¼ difference in value between each participant institution and the core
laboratory; -mean ¼mean of the values at each participant institution and the core laboratory; Exclusion criterion 1 ¼ Interfaces in the longitudinal B-mode images not clear and/or
inadequate due to patient movement; Exclusion criterion 2 ¼ exclusion criteria 1 plus unclear intimaemedia complex signal in the A-mode images.
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demia, and/or diabetes mellitus (Total R2 ¼ 0.289). First, the FMD
values in these 6535 subjects stratiﬁed into different FRS-based CV
risk categories were obtained (Study 2-1-1: Fig. 1). Second, among
the total of 6660 subjects, the age-based reference values of FMD
were examined in 4533 subjects after exclusion of subjects over the
age of 75 years and subjects with cardiovascular risk factors, (Study
2-1-2: Fig. 1). Third, the age-based normal values were examined in
the remaining 1908 subjects who were under 75 years of age and
had no risk factors for cardiovascular disease (Study 2-1-3: Fig. 1).
Then, the subjects were divided by the gender and age (classiﬁed indecades). Fourth, among the study A subjects and subjects with CV
disease from Study C and the FDR study, clear images of the brachial
artery interfaces were obtained in 729 subjects, and the FMD values
in these subjects were determined (Study 2-2: Fig. 1). The clinical
characteristics of the study subjects are shown in Table 1.
Table 2 shows the FMD and DIAbase values in each group clas-
siﬁed by the gender and FRS-based risk category in subjects with
and without CV disease. Table 2 also shows the reference and
normal values of FMD and DIAbase classiﬁed by the gender and age
(classiﬁed in decades).
When subjects with and without CV disease in each FRS-based
Table 2
Flow-mediated vasodilatation of the brachial artery and brachial artery diameter according to the Framingham Risk Score-based cardiovascular risk class and age-based
normal/reference values (median and 95% conﬁdence intervals classiﬁed in decades).
Men CVD Women CVD
nonCVD nonCVD
FRS class
FRS-L n ¼ 3239 n ¼ 237 n ¼ 1185 n ¼ 53
FMD (%) 6.50 (2.30e12.10) 5.10 (1.24e10.61) 6.90 (1.97e13.20) 4.86 (0.28e10.28)
FMDallo (%) 7.55 (2.67e13.94) 5.83 (1.45e12.28) 7.87 (2.28e15.00) 5.63 (0.33e11.73)
DIAbase (mm) 4.13 (3.38e5.00) 4.30 (3.47e5.45) 3.37 (2.72e4.26) 3.59 (2.66e4.67)
FRS-M n ¼ 1486 n ¼ 226 n ¼ 144 n ¼ 29
FMD (%) 5.50 (1.80e10.20) 4.48 (1.06e9.45) 4.72 (0.22e9.32) 4.50 (0.61e8.67)
FMDallo (%) 6.50 (2.01e11.94) 5.26 (1.24e10.97) 5.51 (0.26e10.56) 5.14 (0.71e9.86)
DIAbase (mm) 4.26 (3.50e5.10) 4.35 (3.48e5.44) 3.61 (2.88e4.63) 3.73 (2.83e4.43)
FRS-H n ¼ 462 n ¼ 106 n ¼ 19 n ¼ 13
FMD (%) 5.15 (1.30e9.64) 4.58 (1.02e8.07) 3.25 () 3.74 ()
FMDallo (%) 6.06 (1.59e11.11) 5.32 (1.22e9.35) 3.81 () 4.39 ()
DIAbase (mm) 4.21 (3.52e5.22) 4.29 (3.47e5.44) 3.79 () 4.00 ()
FRS-all n ¼ 5187 n ¼ 569 n ¼ 1348 n ¼ 95
FMD (%) 6.07 (2.00e11.40) 4.67 (1.11e9.73) 6.60 (1.69e13.01) 4.65 (0.29e9.64)
FMDallo (%) 7.09 (2.33e13.19) 5.48 (1.31e11.35) 7.50 (1.97e14.86) 5.33 (0.33e11.00)
DIAbase (mm) 4.17 (3.43e5.06) 4.31 (3.47e5.44) 3.40 (2.74e4.33) 3.73 (2.80e4.70)
Reference values
Age 30- n ¼ 669 n ¼ 8 n ¼ 228 n ¼ 2
FMD (%) 7.05 (3.10e13.18) 3.97 () 8.80 (4.50e14.41) 9.66 ()
FMDallo (%) 8.21 (3.65e15.31) 4.64 () 9.97 (5.16e16.52) 11.03 ()
DIAbase (mm) 3.99 (3.30e4.77) 4.18 () 3.12 (2.66e3.73) 3.49 ()
Age 40- n ¼ 1483 n ¼ 51 n ¼ 291 n ¼ 2
FMD (%) 6.73 (2.60e12.30) 5.77 (1.07e12.02) 7.90 (2.99e15.37) 7.33 ()
FMDallo (%) 7.82 (3.01e14.24) 6.62 (1.27e13.81) 9.06 (3.46e17.45) 8.47 ()
DIAbase (mm) 4.11 (3.37e5.00) 4.27 (3.46e5.32) 3.29 (2.66e4.04) 4.00 ()
Age 50- n ¼ 1228 n ¼ 149 n ¼ 282 n ¼ 17
FMD (%) 5.98 (1.90e10.90) 5.00 (1.27e9.73) 6.31 (1.90e12.39) 5.08 ()
FMDallo (%) 6.99 (2.25e12.59) 5.92 (1.50e11.35) 7.24 (2.10e13.99) 5.87 ()
DIAbase (mm) 4.18 (3.43e4.99) 4.30 (3.55e5.43) 3.40 (2.71e4.22) 3.74 ()
Age 60- n ¼ 275 n ¼ 412 n ¼ 77 n ¼ 88
FMD (%) 5.60 (1.78e10.61) 4.46 (1.02e9.46) 5.45 (2.36e10.61) 4.39 (0.27e8.60)
FMDallo (%) 6.55 (2.07e12.26) 5.20 (1.22e11.03) 6.29 (2.70e11.93) 5.02 (0.31e9.89)
DIAbase (mm) 4.15 (3.29e5.07) 4.32 (3.46e5.45) 3.53 (2.82e4.26) 3.73 (3.02e4.78)
Reference all n ¼ 3665 n ¼ 620 n ¼ 878 n ¼ 109
FMD (%) 6.50 (2.40e11.86) 4.63 (1.10e9.66) 7.40 (2.70e14.09) 4.51 (0.41e9.50)
FMDallo (%) 7.55 (2.82e13.74) 5.41 (1.30e11.28) 8.46 (3.15e15.90) 5.26 (0.47e10.69)
DIAbase (mm) 4.12 (3.38e4.97) 4.30 (3.47e5.43) 3.30 (2.68e4.09) 3.73 (2.89e4.72)
Normal values
Age 30- n ¼ 326 e n ¼ 170 e
FMD (%) 7.15 (3.14e13.57) 8.82 (4.50e13.99) e
FMDallo (%) 8.26 (3.75e15.71) 9.97 (5.17e15.89)
DIAbase (mm) 3.92 (3.20e4.63) 3.11 (2.65e3.73) e
Age 40- n ¼ 565 e n ¼ 183 e
FMD (%) 7.30 (2.61e12.64) e 7.90 (3.32e16.17) e
FMDallo (%) 8.53 (3.06e14.63) 9.06 (3.74e18.12)
DIAbase (mm) 4.01 (3.30e4.94) e 3.26 (2.71e3.95) e
Age 50- n ¼ 394 e n ¼ 142 e
FMD (%) 6.40 (1.90e11.80) e 6.37 (1.05e11.49) e
FMDallo (%) 7.49 (2.26e13.59) 7.27 (1.15e13.12)
DIAbase (mm) 4.13 (3.31e4.94) e 3.41 (2.75e4.08) e
Age 60- n ¼ 90 e n ¼ 38 e
(continued on next page)
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Table 2 (continued )
Men CVD Women CVD
nonCVD nonCVD
FMD (%) 5.73 (1.57e10.41) e 5.56 (2.38e10.67) e
FMDallo (%) 6.71 (1.88e12.03) 6.35 (2.73e12.23)
DIAbase (mm) 4.22 (3.44e5.11) e 3.64 (2.96e4.39) e
nonCVD ¼ subjects without cardiovascular disease; p-value ¼ p-value between subjects with and without cardiovascular disease; FRS-L ¼ subjects classiﬁed according to the
Framingham risk scores in the low risk category; FRS-M ¼ subjects classiﬁed according to the Framingham risk scores into the intermediate risk category; FRS-H ¼ classiﬁed
according to the Framingham risk scores into the high risk category; FRS-all¼ All subjects included in the Framingham risk class stratiﬁcation; Age 30-¼ subjects aged 30e39
years; Age 40-¼ subjects aged 40e49 years; Age 50- ¼ subjects aged 50e59 years; Age 60- ¼ subjects aged over 60 years; reference all ¼ all study subjects included to obtain
reference values; () ¼ number of subjects was not enough to calculate the 95% conﬁdence intervals; other abbreviations are as described in the footnote for Table 1.
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revealed a signiﬁcant power of the FMD to discriminate between
subjects with and without CV disease (Supplementary Table 2); the
area under the curve (AUC) of the ROC was larger in the FRS-based
low-risk category than in the FRS-based intermediate- or high-risk
category (Supplementary Table 2). In all study subjects included to
obtain these reference values, the AUC revealed that the discrimi-
native power of FMD for subjects with CV disease was greater than
that of DIAbase (Supplementary Table 2). In addition, the allometric
scaled FMD did not improve that discriminative power
(Supplementary Table 2). When the subjects with CAD registered
from the two institutions (Study A subjects) with ICC values of
<0.60 (n¼ 19) were excluded (Supplementary Table 1), the AUCs to
discriminate between patients with and without CV disease were
almost similar (data not shown).
4. Discussion
The novelties of the present study are that we attempted to
validate the reliability of assessment of FMD (brachial artery scan
recording and its analysis) across multiple participant institutions
using a semi-automatic device, and to establish the normal and
reference values of FMD based on the FMD data from multiple in-
stitutions measured under a uniform protocol using the semi-
automatic device.
There were two issues concerning the reliability of FMD
assessment at individual institutions that needed to be clariﬁed.
One is the wide variability of FMD values assessed from A-mode
images. Donald et al. reported that FMD values measured by A-
mode wall tracking vary to a greater degree than those assessed
using the B-mode edge detection system, because of the difﬁculty
in maintaining positional stability of a single M-line without 2-
dimensional image guidance [16]. In the present study, however,
adequate A-mode images were obtained under stereotaxic guid-
ance from the B-mode 2-dimensional images. Therefore, this issue
was thought to be overcome by the use of the dedicated ultraso-
nographic device in the present study. Another issue is inter-reader
variability of FMD analysis. Some previous studies have reported a
closer relationship between the results of differentmethods of FMD
analysis (e.g., A-mode analysis vs. B-mode analysis) from the same
scan [17,18]. In these studies, however, the analysis of the scans was
conducted by same reader. Furthermore, while recent multicenter
studies reported that use of a standardized procedure using a
computer-assisted software to analyze the brachial artery scans
after optimal training yielded reproducible FMD values in some
multicenter studies [7,8], the recorded scans were analyzed at the
COLB by a few well-trained operators using such software. In the
present multi-center study, we examined the inter-reader vari-
ability for FMD analysis (i.e., between the reader at each of the
institutions and the reader at the COLB).
The Dal-VESSE study reported that the intra-class correlation
coefﬁcient range of the inter-reader reliability of the FMD values, asassessed by a B-mode device, among the readers of the core labo-
ratory was 0.82e0.87 [7]. Brooks et al. reported that the standard
deviation of difference of the FMD values assessed by a B-mode
device between two readers was 2.32% [19]. In these studies, the
subjects with inadequate images of the vessel interfaces were
excluded. In the present study, in which the operators conducted
the measurement after obtaining certiﬁcation (optimal training
under a uniform protocol using the same semi-automatic device
was provided to the operators) [9], the results revealed a good
correlation between the FMD assessment conducted at each insti-
tution and the FMD-COLB when cases with inadequate brachial
artery scan images were excluded. The correlation co-efﬁcient of
FMD value (r ¼ 0.838) and the standard deviation of difference of
the FMD values as assessed by A-mode imaging (1.55%) between
each institution and the COLB were similar to those for the B-mode
images. While all the participating institutions had received certi-
ﬁcation as to their ability for accurate assessment of FMD based on a
training session provided to them before they started patient
registration for the FMD-J study (Supplementary ﬁle 3), the reli-
ability was found to be unsatisfactory for two institutions which
received only a small number of subjects for the assessment of
FMD. Thus, as described in the guideline [6], after training for the
assessment of FMD, attending periodic refresher courses in FMD
assessment may be needed for the maintenance of competency.
In addition to the aforementioned instability of maintenance of
position of a single M-line without 2-dimensional image guidance,
we hypothesized that unclear signals of the IMC in the A-mode
images may be another reason for the wide variability of FMD value
assessed by the A-mode device. In the present study, however, the
correlation coefﬁcient between the FMD values measured at each
institution and the COLB and the distributions of the BlandeAltman
plots of the difference of the FMD values between each institution
and the COLB were similar after exclusion based on exclusion cri-
terion 1 and exclusion criterion 2. Thus, the unclear signal of the
IMC in the A-mode images may not be a signiﬁcant cause of the
wide variability of the FMD value.
It is known that the protocol used (i.e., technical aspects such as
lower arm/upper arm occlusion or occlusion duration) can affect
the FMD value [20]. Even so, the protocols for the assessment of
FMD in previously conducted multicenter studies were diverse
[4,5,7e9,20], and the number of study subjects in these studies
ranged from 2000 to 3,000, and all of these data were analyzed by
the COLB. The strength of the present study was that reference
values of FMD were established based on the data of more than
6000 study subjects obtained using a uniform protocol at each
participating institution that fulﬁlled the criteria for certifying the
reliability of the assessment.
Consistent with the results of previous studies [10e12], age,
gender and FRS were signiﬁcant determinants of FMD in the pre-
sent study. Then, with the patients classiﬁed by the FRS-based CV
risk category and by the gender, and normal/reference values were
set according to the age (classiﬁed in decades) in both genders.
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discriminate CV disease was larger in the FRS-based low-cardio-
vascular risk category as compared to that in the FRS-based inter-
mediate- or high-risk group in both genders. Similar ﬁndings were
reported by Witte et al., therefore, FMD may be related to the
estimated 10-year risk for CAD, especially in subjects with a low
risk for CV disease [21]. In addition, the AUC to discriminate CV
disease was signiﬁcant in subjects inwhom the FMD values were in
the present range of reference values. These results suggest that
FMD values in the FRS-based risk classes (especially the low-risk
group) and the age-based reference range may represent a state
without advanced atherosclerotic vascular damage.
The present study had some limitations, as follows; 1) The re-
ported rejection rate of scans from previous studies is in the range
of 10e30% [7,8]. In the present study, the rejection rate was 10%.
Thus, it is necessary to recognize that, in the present state, this FMD
assessment method may not be applicable to all subjects. For such
cases, reactive hyperemia peripheral arterial tonometry is available
for the assessment of endothelial function [22], but it should be
taken into account that FMD and peripheral tonometry reﬂect
different facets of the pathophysiological abnormalities of vascular
endothelium [22,23]; 2) Further studies are needed to clarify
whether the reference and normal FMD values determined in the
present study might also be applicable to other ethnicities; 3) The
edge-detection system improves the accuracy of determination of
the diameter by multiple-point detection [24]. The device in the
present study determined the diameter at 21 points in a 3-mm
segment of the longitudinal B-mode image [9]; 4) The present
study did not validate some technical aspects that might affect the
FMD value (e.g., cuff occlusion pressure, area of placement of the
cuff subject preparation) [6,20]; 5) DIAbase has also been reported
as a marker to predict future CV events [25], and in the present
study also, DIAbase allowed discrimination between subjects with
and without CV disease. Therefore, in the prospective study arms of
the FMD-J study, the comparison of the usefulness of FMDwith that
of DIAbase to predict the outcomes is proposal; 6) The Doppler ﬂow
values to obtain the shear rate [26] is automatically calculated by
the device used in the present study, therefore, the reliability of
Doppler ﬂow values measured by the present device was not
evaluated in the present study; 7) Endothelial-independent vaso-
dilatation was not assessed in the FMD-J study.5. Conclusion
When the analysis was limited to cases with clear FMD re-
cordings (about 90% of cases), the reliability of the FMD assessment
(scan and its analysis) with a semi-automatic device conducted in
individual institutions appeared to be acceptable, but attending
periodic refresher courses in FMD assessment may be needed for
the maintenance of competency. Reference FMD values (lower cuff
occlusion) for the Japanese population are proposed based on
reliable data derived from multiple institutions, and the reference
values may identify patients with values in the reference ranges
may be in a state without advanced atherosclerotic vascular
damage.Funding sources
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